Phase 3 N=75 Treatment of Mania Symptoms With Drug Therapy
Bipolar Disorder · Schizophrenia
Primary: Symptoms of Mania, as Measured by Young Mania Rating Scale — 5.7; 11.1; 10.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=238 Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
Bipolar Disorder
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -8.91; -15.02 score on a scale — p=<0.0001
Phase 3 N=258 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -11.3; -5.3 scores on a scale — p=<0.001
Phase 4 N=376 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
Acute Mania in Bipolar Disorder
Primary: Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28) — -25.7; -26.1 score on a scale
Phase 3 N=322 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
Bipolar I Disorder · Manic Episode
Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -10.6; -10.8 units on a scale — p==0.8797
N/A N=14 Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation
Bipolar Disorder · Schizo Affective Disorder
Primary: Young Mania Rating Scale (YMRS) — 5.5; 11.8; 7.5; 3 score on a scale
Phase 3 N=312 Safety and Efficacy of Cariprazine for Mania
Bipolar Disorder · Mania
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -15.3; -19.6 score on a scale — p=0.0004
Phase 3 N=333 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
Bipolar I Disorder · Manic Episode
Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -12.3; -10.7 units on a scale — p==0.1011
Phase 4 N=27 Allopurinol Add-on Treatment for Refractory Mania
Bipolar Disorder · Mixed Mania · Treatment-Resistant Mania
Primary: Young Mania Rating Scale (YMRS) — -12.3; -9.6 units on a scale — p=.45
Phase 3 N=224 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
Bipolar Disorder
Primary: Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score — -12.6; -14.3; -6.8 units on a scale — p=<0.001
N/A N=13 Examining the Effect of EEG-guided Theta Burst Stimulation in Bipolar Disorder
Bipolar Disorder
Primary: Brain Activity (Beta Power) in Left vLPFC — -88.78; 1437.64; 13.43; -128.00 Percentage of change post versus pre — p=0.29389090
Phase 4 N=224 Treatment of Bipolar Mania in Older Adults
Bipolar Disorder · Mania
Primary: Sedation Score — 0.5; 0.5; 0.6; 0.6 units on a scale
Phase 3 N=680 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
Bipolar Disorder
Primary: Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS) — -10.19; -10.95; -9.47 scores on scale — p=0.1077
Phase 3 N=41 A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -18.8 scores on a scale
Phase 3 N=34 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence
Mania · Hypomania · Cocaine Abuse
Primary: Cocaine Use Determined by Urine Analysis — 62.50; 50.00 percentage of participants no cocaine — p=.4637
Phase 4 N=1,270 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
Bipolar Disorder
Primary: Proportion of Participants Not Experiencing Relapse to Any Mood Episode Through Week 52, Phase 3 — 1.00; 1.00; 0.95; 0.96 proportion of participants — p=0.014
Phase 4 N=356 Adult Bipolar Mania
Acute Mania
Primary: Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) — -22.8; -20.1 Scores on a scale
Phase 3 N=218 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
Bipolar Disorder
Primary: Participants Who Experienced Adverse Event(s) — 23; 68; 85 Participants
Phase 3 N=67 A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
Mania (Neurotic)
Primary: Rate of Relapse — .11; .13 Proportion of Participants
Phase 4 N=202 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
Bipolar I Disorder
Primary: Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint. — -10.15; -7.68 units on a scale — p=<0.001
Phase 4 N=51 Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
Bipolar Disorder · Mania
Primary: Change of Mania Symptoms Assessed by Young Mania Rating Scale (YMRS) — -14.9 Units on a scale
Phase 3 N=60 Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
Bipolar Disorder
Primary: Time in Weeks to Discontinuation — 25.93; 3.00 time in weeks to discontinuation
Phase 3 N=414 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Bipolar I Disorder
Primary: Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score — -14.0; -10.0 Change from Baseline in YMRS Total Score